Similar Articles
311 Systemic treatment for unresectable hepatocellular carcinoma
312 Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
313 Predictors of early and late hepatocellular carcinoma recurrence
314 Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin
315 Current status and prospect of treatments for recurrent hepatocellular carcinoma
316 Network meta-analysis of the prognosis of curative treatment strategies for recurrent hepatocellular carcinoma after hepatectomy
317 Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis
318 Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
319 Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma
320 Treatment of recurrent hepatocellular carcinoma following liver resection, ablation or liver transplantation
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA